Industry Events

Events

    Richter announces the acquisition of Finox Holding

    30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million.   Finox Holding, a Swiss based biotech company engaged in the development and commercialisation of innovative and cost effective products addressing female fertility. Finox Holding product BEMFOLA® is a biosimilar r-hFSH, which stimulates the ovaries in order to treat infertility. Richter obtains global rights […]Read More

    Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

    DUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, — Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids. The study included 157 patients, with 101 patients randomized to ulipristal acetate 5 and 10mg […]Read More

    Full Results of PEARL IV Study presented at the European Society of Gynaecological Endoscopy (ESGE) congress confirms the efficacy of ulipristal acetate 5 mg for the long term management of uterine fibroids

    Budapest, 12 October 2015 – Gedeon Richter Plc. (“Richter”) announces results of the PEARL IV study at ESGE. PEARL IV was a Phase III, randomized, double-blind, parallel group study investigating the efficacy and safety of repeated 3 months treatment courses of daily 5mg or 10mgᵃ ulipristal acetate (UPA) for the long-term management of symptomatic uterine fibroids, characterized by heavy bleeding.¹ […]Read More

    European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)

    Budapest, Hungary – 28 May 2015 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted approval for the intermittent use of Esmya® 5 mg in the long term management of uterine fibroids. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 […]Read More

Past and future industry events

You will find here the industry events where we are present.

Send this to friend